atacicept
Asset
Recombinant fusion protein inhibiting BAFF and APRIL to reduce pathogenic IgA production.
- Stage
- Phase 3
- Modality
- Protein or enzyme
- Target
- Inflammation
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Berger disease
Phase 3, Active not recruiting, NCT04716231, clinicaltrials.gov, 7 Oct 2026
IgA nephropathy
Phase 3, Active not recruiting, NCT04716231, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1
- Evidence for its targets3
- Competitors2
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 1 source